PIK3CA and pancreatic neoplasm: One patient with PIK3CA mutant pancreatic cancer who was treated with an inhibitor of the PI3K pathway has been described.37 This patient's cancer had progressed through multiple standard lines of chemotherapy, but even in the treatment-refractory setting, their cancer responded significantly to targeting the PI3K pathway.